LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer.

    Mitsogianni, Maria / Papatsoris, Athanasios / Bala, Vanessa-Meletia / Issa, Hussein / Moussa, Mohammad / Mitsogiannis, Iraklis

    Expert opinion on pharmacotherapy

    2023  Volume 24, Issue 16, Page(s) 1765–1774

    Abstract: Introduction: Prostate cancer is the most common malignancy in the male. Androgen-deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate cancer however, due to the outgrowth of castration-resistant cell population the ... ...

    Abstract Introduction: Prostate cancer is the most common malignancy in the male. Androgen-deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate cancer however, due to the outgrowth of castration-resistant cell population the disease inevitably progresses to an aggressive, difficult to handle stage.
    Areas covered: We have reviewed the literature regarding hormonal-directed therapy prostate cancer. New agents, namely abiraterone acetate, combined with prednisone, and next generation antiandrogens (enzalutamide, apalutamide and darolutamide) have shown considerable efficacy, not only in patients with metastatic but also in those with non-metastatic disease, either castration resistant (CRPC) or hormone sensitive (HSPC).
    Expert opinion: The addition of abiraterone and of the second-generation antiandrogens to our therapeutic armamentarium has improved prognosis ofprostate cancer in the last decade. Abiraterone is a viable option in patients with metastatic disease (hormone-sensitive and castration-resistant), whereas all next-generation antiandrogens have demonstrated efficacy in terms of metastasis-free and overall survival in non-metastatic CRPC. In addition, enzalutamide has also been found efficacious in mCRPC and mHSPC, while apalutamide in mHSPC. Currently there are no reliable data to indicate a potential superiority of one of these agents over the others in CRPC or HSPC as there are no relevant head to head studies . Sequencing hormone treatment modalities, chemotherapies and immunotherapies have not reached a consensus as yet. Randomized controlled trials are warranted to clearly define the role of novel antiandrogens in the treatment of prostate cancer. The choice of treatment should be individualized following discussion with the patient .
    MeSH term(s) Humans ; Male ; Prostatic Neoplasms, Castration-Resistant ; Androgen Antagonists/therapeutic use ; Treatment Outcome ; Hormones/therapeutic use
    Chemical Substances enzalutamide (93T0T9GKNU) ; Androgen Antagonists ; Hormones
    Language English
    Publishing date 2023-08-07
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2244415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Nanoparticle-Mediated Hyperthermia and Cytotoxicity Mechanisms in Cancer.

    Bala, Vanessa-Meletia / Lampropoulou, Dimitra Ioanna / Grammatikaki, Stamatiki / Kouloulias, Vassilios / Lagopati, Nefeli / Aravantinos, Gerasimos / Gazouli, Maria

    International journal of molecular sciences

    2023  Volume 25, Issue 1

    Abstract: Hyperthermia has the potential to damage cancerous tissue by increasing the body temperature. However, targeting cancer cells whilst protecting the surrounding tissues is often challenging, especially when implemented in clinical practice. In this ... ...

    Abstract Hyperthermia has the potential to damage cancerous tissue by increasing the body temperature. However, targeting cancer cells whilst protecting the surrounding tissues is often challenging, especially when implemented in clinical practice. In this direction, there are data showing that the combination of nanotechnology and hyperthermia offers more successful penetration of nanoparticles in the tumor environment, thus allowing targeted hyperthermia in the region of interest. At the same time, unlike radiotherapy, the use of non-ionizing radiation makes hyperthermia an attractive therapeutic option. This review summarizes the existing literature regarding the use of hyperthermia and nanoparticles in cancer, with a focus on nanoparticle-induced cytotoxicity mechanisms.
    MeSH term(s) Humans ; Hyperthermia ; Nanoparticles ; Neoplasms/therapy ; Hyperthermia, Induced
    Language English
    Publishing date 2023-12-25
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25010296
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature.

    Bala, Vanessa-Meletia / Mitsogianni, Maria / Laschos, Konstantinos / Pliakou, Evangelia / Lazaridi, Eirini / Lampropoulou, Dimitra-Ioanna / Aravantinos, Gerasimos

    Molecular and clinical oncology

    2022  Volume 16, Issue 5, Page(s) 99

    Abstract: BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF-mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case ... ...

    Abstract BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF-mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case of a patient with metastatic melanoma developing a sarcoid-like reaction manifesting as asymptomatic mediastinal and right hilar lymphadenopathy while on antineoplastic therapy with dabrafenib and trametinib. To the best of our knowledge, this is the first reported case of isolated lymphadenopathy as a manifestation of drug-induced sarcoid-like reaction under dabrafenib and trametinib. Overall, only 17 other cases of granulomatosis have been reported in the literature. Although uncommon, such reactions should be considered in the differential diagnosis of lymph node enlargement, and distinguishing them from tumor progress is important and can be challenging in clinical practice.
    Language English
    Publishing date 2022-03-18
    Publishing country England
    Document type Case Reports
    ZDB-ID 2796865-0
    ISSN 2049-9469 ; 2049-9450
    ISSN (online) 2049-9469
    ISSN 2049-9450
    DOI 10.3892/mco.2022.2532
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection.

    Lampropoulou, Dimitra Ioanna / Bala, Vanessa Meletia / Zerva, Eleni / Pliakou, Evangelia / Filippou, Dimitrios / Gazouli, Maria / Aravantinos, Gerasimos

    Journal of infection in developing countries

    2022  Volume 16, Issue 1, Page(s) 101–111

    Abstract: Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.: Methodology: We ... ...

    Abstract Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
    Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.
    Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.
    Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.
    MeSH term(s) COVID-19/drug therapy ; COVID-19/epidemiology ; Humans ; Pandemics ; Patient Acuity ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; SARS-CoV-2 ; Vascular Endothelial Growth Factor A/pharmacology
    Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors ; Vascular Endothelial Growth Factor A
    Language English
    Publishing date 2022-01-31
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 2394024-4
    ISSN 1972-2680 ; 2036-6590
    ISSN (online) 1972-2680
    ISSN 2036-6590
    DOI 10.3855/jidc.15386
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top